Many of our technologies are built and designed in-house to automate the selection and isolation of individual antibody-producing immune cells. We design microfluidic devices, each capable of physically isolating many thousands of single cells to allow customized antibody screening assays. We use robotics and machine vision to image each chamber of our devices and select for antibody-specific hits, followed by automated recovery of the antibody-producing cells for sequencing. Our goal is to continuously push the throughput, capacity, and robustness of our system in search of rare and potent antibodies.